(2) THIS SUBSECTION DOES NOT APPLY TO EXPERIMENTAL DRUGS,
INVESTIGATIONAL DRUGS, PRESCRIPTIONS AND INJECTIONS FOR CENTRAL
NERVOUS SYSTEM STIMULANTS AND ANORECTIC AGENTS WHEN USED FOR WEIGHT
CONTROL, OR DRUGS USED FOR COSMETIC PURPOSES.

(F) (1) (I) THE MARYLAND HEALTH CARE ACCESS AND COST COMMISSION
SHALL DEVELOP AND IMPLEMENT A SYSTEM OF RATING THE PRESCRIPTION DRUG
COVERAGE PLANS OFFERED BY ENTITIES SUBJECT TO THIS SECTION TO ASSIST
EMPLOYERS AND CONSUMERS IN EVALUATING AND SELECTING A PLAN.

(II) THE COMMISSION SHALL ESTABLISH A CONSUMER ADVISORY
PANEL CONSISTING OF 13 MEMBERS TO ADVISE THE COMMISSION IN DEVELOPING
AND IMPLEMENTING THE RATING SYSTEM REQUIRED UNDER SUBPARAGRAPH (I) OF
THIS PARAGRAPH.

(II) THE PANEL SHALL CONSIST OF A REPRESENTATIVE OF:

1. THE NATIONAL COALITION FOR CANCER SURVIVORSHIP;

2. THE NATIONAL KIDNEY FOUNDATION;

3. THE MARYLAND MENTAL HEALTH ASSOCIATION;
4. THE AMERICAN DIABETES ASSOCIATION;

5. THE AMERICAN HEART ASSOCIATION;
6. THE AMERICAN LUNG ASSOCIATION;
7. THE ARTHRITIS FOUNDATION;
8. THE MEDICAL AND CHIRURGICAL FACULTY;
9. THE MARYLAND PHARMACISTS ASSOCIATION;
10. THE AMERICAN ACADEMY OF PEDIATRICS, MARYLAND

CHAPTER;

11. THE AMERICAN ACADEMY OF OBSTETRICIANS AND
GYNECOLOGISTS; AND

12. THE MARYLAND PATIENT ADVOCACY GROUP.

(2) AN ENTITY SUBJECT TO THIS SECTION, IN ANY DOCUMENTS THAT
DESCRIBE A PRESCRIPTION DRUG COVERAGE PLAN OFFERED BY THE ENTITY AND
THAT ARE PROVIDED TO AN EMPLOYER OR MEMBER, SHALL INCLUDE:

(I) IN THE UPPER LEFT HAND CORNER OF THE FIRST PAGE OF
EACH DOCUMENT, THE RATING DESIGNATION ASSIGNED TO THE PLAN BY THE
COMMISSION; AND

(II) AN EXPLANATION OF THE RATING SYSTEM AND THE RATING
DESIGNATION ASSIGNED TO THE PLAN.